The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: A systematic review and meta-analysis

Liu, Shiru; Kasherman, Lawrence; Fazelzad, Rouhi; Wang, Lisa; Bouchard-Fortier, Geneviève; Lheureux, Stéphanie; Krzyzanowska, Monika K.

doi:10.1016/j.ygyno.2021.01.028

Cited by 22 publications

(27 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many kinds of drugs are used to treat tumours. For example, bevacizumab is used to treat advanced ovarian cancer, 39 metastatic colorectal cancer 40 and non-small cell lung cancer. 41 Bicalutamide is used to treat metastatic hormone-sensitive prostate cancer.…”

Section: Discussionmentioning

confidence: 99%

Bioinformatics Analysis of Choriocarcinoma-Related MicroRNA-Transcription Factor-Target Gene Regulatory Networks and Validation of Key miRNAs

Peng¹,

Zhang²,

Mo³

et al. 2021

OTT

View full text Add to dashboard Cite

Objective The aim of the current research was to construct a miRNA-transcription factor (TF)-target gene regulatory network in order to investigate the mechanism underlying choriocarcinoma and to verify the network through the overexpression or silencing of hub miRNAs in vitro. Materials and Methods A mRNA expression dataset and two miRNA expression datasets were analysed to identify differentially expressed genes (DEGs) and miRNAs (DEMs) between normal cells and choriocarcinoma cells. The top 400 upregulated and downregulated DEGs were identified as candidate DEGs, which were then mapped to construct protein–protein interaction (PPI) networks and select hub genes. Moreover, the DGIdb database was utilized to select candidate drugs for hub genes. Moreover, DEM target genes were predicted through the miRWalk2.0 database and overlaid with candidate DEGs to identify the differentially expressed target genes (DETGs). Furthermore, we established miRNA-TF-target gene regulatory networks and performed functional enrichment analysis of hub DEMs. Finally, we transfected mimics or inhibitors of hub DEMs into choriocarcinoma cells and assessed cell proliferation and migration to verify the vital role of hub DEMs in choriocarcinoma. Results A total of 140 DEMs and 400 candidate DEGs were screened from choriocarcinoma cells and normal cells. A PPI network of 400 candidate DEGs was established. Twenty-nine hub genes and 99 associated small molecules were identified to provide potential target drugs for choriocarcinoma treatment. We obtained 70 DETGs of DEMs derived from the intersection between predicted miRNA target genes and candidate DEGs. Subsequently, 3 hub DEMs were selected, and miRNA-TF-target gene regulatory networks containing 4 TFs, 3 TFs and 3 TFs for each network were constructed. The RT-PCR results confirmed that miR-29b-3p was highly expressed and that miR-519c-3p and miR-520a-5p were expressed at low levels in choriocarcinoma cells. The overexpression or silencing results suggested that 3 dysregulated hub DEMs jointly accelerated the proliferation and migration of choriocarcinoma. Conclusion Association of miRNA-TF-target gene regulatory networks may help us explore the underlying mechanism and provide potential targets for the diagnosis and treatment of choriocarcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Bioinformatics Analysis of Choriocarcinoma-Related MicroRNA-Transcription Factor-Target Gene Regulatory Networks and Validation of Key miRNAs

Peng¹,

Zhang²,

Mo³

et al. 2021

OTT

View full text Add to dashboard Cite

show abstract

Section: Current Therapies For Epithelial Ovarian Cancermentioning

confidence: 99%

“…To a better understanding of the real benefit of using bevacizumab in ovarian cancer patients, a meta-analysis that included 7 studies with patients with advanced ovarian cancer was performed [ 88 ]. This study concluded that bevacizumab treatment increased progression-free survival in patients with both advanced and recurrent disease, but its use was associated with an increase of overall survival only in patients with recurrent disease [ 88 ]. Although bevacizumab therapy is extended to many countries and is considered one of the greatest advances in the treatment of ovarian cancer, some researchers consider that this therapy could be not cost-effective [ 89 , 90 ].…”

Section: Current Therapies For Epithelial Ovarian Cancermentioning

confidence: 99%

Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer

et al. 2021

View full text Add to dashboard Cite

Epithelial ovarian cancer (EOC) is one of the deadliest gynaecological malignancies. The late diagnosis is frequent due to the absence of specific symptomatology and the molecular complexity of the disease, which includes a high angiogenesis potential. The first-line treatment is based on optimal debulking surgery following chemotherapy with platinum/gemcitabine and taxane compounds. During the last years, anti-angiogenic therapy and poly adenosine diphosphate-ribose polymerases (PARP)-inhibitors were introduced in therapeutic schemes. Several studies have shown that these drugs increase the progression-free survival and overall survival of patients with ovarian cancer, but the identification of patients who have the greatest benefits is still under investigation. In the present review, we discuss about the molecular characteristics of the disease, the recent evidence of approved treatments and the new possible complementary approaches, focusing on drug repurposing, non-coding RNAs, and nanomedicine as a new method for drug delivery.

show abstract

“…Another angiogenesis inhibitor, lenvatinib, has also recently obtained regulatory approval, in combination with pembrozliumab, for subsequent-line treatment of advanced endometrial cancer [ 2 ]. However, despite having demonstrable benefits compared with chemotherapy alone [ 3 , 4 ], most patients will inevitably experience disease progression, with a proportion of patients experiencing relatively limited periods of disease control. This highlights the pressing need to develop molecular and other biomarkers to improve patient selection by predicting who may respond to these therapies, in addition to developing therapeutic strategies to overcome drug resistance.…”

Section: Introductionmentioning

confidence: 99%

Angiogenesis: A Pivotal Therapeutic Target in the Drug Development of Gynecologic Cancers

Kasherman

Liu

Karakasis

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

Since the discovery of angiogenesis and its relevance to the tumorigenesis of gynecologic malignancies, a number of therapeutic agents have been developed over the last decade, some of which have become standard treatments in combination with other therapies. Limited clinical activity has been demonstrated with anti-angiogenic monotherapies, and ongoing trials are focused on combination strategies with cytotoxic agents, immunotherapies and other targeted treatments. This article reviews the science behind angiogenesis within the context of gynecologic cancers, the evidence supporting the targeting of these pathways and future directions in clinical trials.

show abstract

The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: A systematic review and meta-analysis

Cited by 22 publications

References 42 publications

Bioinformatics Analysis of Choriocarcinoma-Related MicroRNA-Transcription Factor-Target Gene Regulatory Networks and Validation of Key miRNAs

Bioinformatics Analysis of Choriocarcinoma-Related MicroRNA-Transcription Factor-Target Gene Regulatory Networks and Validation of Key miRNAs

Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer

Angiogenesis: A Pivotal Therapeutic Target in the Drug Development of Gynecologic Cancers

Contact Info

Product

Resources

About